TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today neurology roundup published Oct. 27, 2026, highlights three studies on Alzheimer’s or dementia-related questions. The reported findings include an association between head shape and Alzheimer’s pathology, improved IQ test performance in children whose mothers received prenatal phosphatidylcholine in a randomized trial, and genetic scores that may affect aspirin’s relationship with dementia prevention. The findings do not establish that head shape causes Alzheimer’s, that supplements raise IQ in all children, or that aspirin prevents dementia for particular people.
A MedPage Today neurology roundup published Oct. 27, 2026, summarized research linking head shape with Alzheimer’s disease pathology, a randomized trial of prenatal phosphatidylcholine supplements and children’s outcomes, and an analysis suggesting genetic differences may influence how aspirin relates to dementia risk. The reports raise questions about risk, early-life nutrition and prevention, but the roundup does not establish that changing head shape, taking choline, or using aspirin prevents Alzheimer’s disease or dementia.
The item on head shape, cited to the journal Alzheimer’s & Dementia, asks whether head shape can influence Alzheimer’s pathology. The supplied report provides no study design, participant numbers, measurements, or results for that research. It therefore does not support a more specific conclusion about the direction or strength of any relationship, or whether head shape is a cause, a marker, or unrelated after accounting for other factors.
The prenatal nutrition finding came from a randomized trial reported in the American Journal of Obstetrics and Gynecology. Children whose mothers received prenatal phosphatidylcholine supplements had lower social-withdrawal problems and higher IQ test performance through age 4, according to the roundup. The trial did not find a reduction in attention problems. The summary does not give the number of participants, supplement dose, size of the differences, or whether the findings persisted beyond age 4.
A third item, citing ASPREE trial data and Alzheimer’s & Dementia, said platelet-count polygenic scores may influence how aspirin might prevent dementia. The roundup framed the result as a suggestion that some subgroups of older adults could benefit. It does not report which genetic-score groups had what outcomes, or establish a treatment recommendation. Aspirin use can have risks, so these findings should not be read as advice to start or stop it.
Three Findings, Different Evidence
Together, the reports touch on different stages of life and different kinds of evidence: possible biological factors in Alzheimer’s pathology, an intervention during pregnancy with outcomes measured in young children, and a possible interaction between inherited traits and aspirin in older adults. Their relevance is that they may help researchers identify questions for further testing, not that they offer immediate answers for individual patients.
The distinctions matter for readers making health decisions. A reported association is not proof of cause, a trial result in one population may not apply to everyone, and a genetic-score finding does not establish that a drug’s benefits outweigh its harms. The roundup’s short descriptions also leave key details unavailable, including effect sizes and study limitations. Those details are needed to judge how robust or clinically useful the findings may be.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Oral-B iO Series 5 Rechargeable Electric Toothbrush with Travel Case and 3 Brush Heads, Black
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
Research Across the Lifespan
The three items appeared in a broader neurology and neuroscience roundup by Judy George, MedPage Today’s deputy managing editor, rather than as a single study or coordinated research project. The page also listed unrelated developments, including a U.K. platform trial testing repurposed drugs for Alzheimer’s disease, research on cognitive resilience, and a cohort analysis of amyloid onset by race. Those items provide a sense of the range of research covered, but they do not validate the three findings discussed here.
The aspirin item specifically refers to ASPREE trial data, while the prenatal choline report describes a randomized trial and the head-shape item is identified only by its journal citation and question. Because the roundup does not provide full methods or numerical results, its summaries should be treated as pointers to studies, not substitutes for the original papers. The available source material gives no publication dates for the individual studies beyond the roundup’s publication date.
Limits of the Reported Findings
The supplied source is a brief roundup, not the full research papers. For the head-shape study, it provides no results or methods at all. For the prenatal trial, it omits the sample size, dose, effect sizes, and information about longer-term follow-up. For the aspirin analysis, it does not specify the relevant genetic-score groups, the size of any difference, or whether the analysis demonstrates a causal effect.
It is also unclear whether any of these findings have been independently replicated or are ready to guide clinical practice. The choline result applies to outcomes measured through age 4 in the reported trial; it does not establish lasting effects or broad benefit for all pregnancies. The aspirin result does not show that people should take aspirin to prevent dementia. Readers should consult clinicians about supplements or medication decisions, particularly when pregnancy or bleeding risks are involved.
Full Studies Will Clarify Results
The next step for readers and clinicians is to examine the original journal papers for study methods, participant characteristics, numerical results, and limitations. Follow-up research will be needed to determine whether the head-shape association holds in other populations, whether the prenatal phosphatidylcholine outcomes continue beyond age 4, and whether the aspirin-related genetic pattern is replicated and clinically meaningful.
Until those details and further evidence are available, the roundup supports a measured conclusion: these are research signals, not established prevention strategies. No specific clinical guidance or follow-up timetable is provided in the source material.
Key Questions
Does head shape cause Alzheimer’s disease?
The roundup raises a question about head shape and Alzheimer’s pathology but provides no study results establishing a cause. The nature and strength of any relationship are unclear from the supplied information.
Did prenatal choline improve children’s IQ?
A randomized trial summary reported higher IQ test performance through age 4 among offspring whose mothers received phosphatidylcholine supplements. The source does not provide effect sizes or show whether the results persist after age 4, so it does not establish a general or lasting benefit.
Did the prenatal supplement reduce attention problems?
No. The roundup says the trial did not find a reduction in attention problems, even though it reported lower social-withdrawal problems and higher IQ test performance.
Should older adults take aspirin to prevent dementia?
The ASPREE-related analysis suggests platelet-count genetic scores may affect aspirin’s relationship with dementia prevention, but it does not establish who should take aspirin or prove a preventive benefit. Aspirin can cause harm, so medication decisions should be discussed with a health professional.
Source: rss
